Medication info

Stavaster Tablets 10 mg (Rosuvastatin Calcium)

Prescription medicationApproval withdrawn
Ingredient · strength
Rosuvastatin Calcium›Strength being verified
Manufacturer / importer
SANDOZ KOREA
Appearance
Brown round film-coated tablet
Packaging
28 tablets/Alu-Alu (7 tablets/Alu-Alu x 4)
Approval status
Approval withdrawn

MFDS item code 201404478 · Approved 2014.09.30

This product's status changed to Approval withdrawn on 2023.06.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goals, and patient response, and may be increased up to a maximum of 20 mg daily. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.
Children's dosage
Ages 10 to 17 years: The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on administration of doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy in children under 10 years of age have not been established.

Ingredients

Importer
SANDOZ KOREA

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • coronary artery disease
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
View approved original text

This drug is used as an adjunct treatment when dietary management and exercise alone are insufficient for patients with hypercholesterolemia and mixed hyperlipidemia. It is particularly useful for patients with heterozygous and homozygous familial hypercholesterolemia, lowering total cholesterol and LDL cholesterol levels to delay the progression of atherosclerosis. It is also effective in children over 10 years of age with high LDL cholesterol when used alongside dietary management. Additionally, it aids in the treatment of dysbetalipoproteinemia. In middle-aged men and women who are at high risk for cardiovascular disease, it contributes to reducing the risk of stroke, myocardial infarction, and revascularization procedures. Thus, it is effectively used for improving blood lipid levels and reducing the risk of cardiovascular diseases.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goals, and patient response, and may be increased up to a maximum of 20 mg daily. 3. Older adults: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose is contraindicated in some of these patients.

Children's dosage

Ages 10 to 17 years: The usual dose range is 5 mg to 20 mg once daily. (There are no clinical data on administration of doses greater than 20 mg in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years of age: Safety and efficacy in children under 10 years of age have not been established.

Precautions

This drug should not be administered to certain patients. For example, individuals who are allergic to any of the components of this drug or have active liver disease should not take it. Patients with muscle disorders or those taking cyclosporine, as well as those with severely impaired kidney function, may also risk complications from using this drug. Pregnant or breastfeeding women, and fertile women who do not use adequate contraception should not use this drug, and women who may become pregnant must consult their doctor. A dosage of 40 mg is particularly contraindicated for patients at high risk of muscle disorders. This drug contains lactose, so those with lactose intolerance or associated genetic disorders should not take it. This drug can affect liver function, so patients with a history of liver disease or those who consume alcohol heavily should use it with caution, and undergo regular liver function tests before and during treatment. If symptoms of muscle pain or weakness occur, inform a doctor immediately. In severe cases, discontinuation of the drug may be necessary. Particular care should be taken in patients with impaired kidney function, hypothyroidism, or a history of genetic muscle disorders regarding signs of muscle distress. This drug can rarely cause side effects such as skin rash, itching, headache, dizziness, indigestion; very rarely, serious skin reactions, liver damage, or muscle rupture have been reported. If abnormal symptoms occur, consult medical personnel promptly. This drug may interact with other medications, so if you are taking any other medications, be sure to inform your doctor, especially when used with certain antivirals, antibiotics, immunosuppressants, or fibrate class drugs. Pregnant or breastfeeding women should not use this drug, and women planning pregnancy should use appropriate contraceptive methods. In the case of overdose, as there is no specific antidote, treatment should be symptomatic, with monitoring of liver function and muscle enzyme levels. Caution is necessary as dizziness may occur when driving or operating machinery.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, increased AST, joint pain, fatigue, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, abnormal liver function tests, syncope, systemic pain

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a tightly sealed container to protect it from air and moisture, and it is recommended to keep it at a temperature between 1 to 30 degrees Celsius. Storing it this way helps maintain its efficacy and prevent degradation.

Appearance and packaging

Appearance

Brown round film-coated tablet

Package unit

28 tablets/Alu-Alu (7 tablets/Alu-Alu x 4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.